Trials / Completed
CompletedNCT00719212
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Translational Research in Oncology · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AMG 479 | Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2008-07-21
- Last updated
- 2016-01-11
- Results posted
- 2015-12-01
Locations
37 sites across 7 countries: United States, Canada, France, Germany, Ireland, Israel, Spain
Source: ClinicalTrials.gov record NCT00719212. Inclusion in this directory is not an endorsement.